Erica Bäckström

Dr. Erica Bäckström


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
EBErica Bäckström
Erica Bäckström
EBElin Boger
Elin Boger
ALAnders Lundqvist
Anders Lundqvist
MHMargareta Hammarlund-Udenaes
Margareta Hammarlund-Udenaes
MFMarkus Fridén
Markus Fridén

1 February 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KRKatarina Rubin
Katarina Rubin
PEPär Ewing
Pär Ewing
EBErica Bäckström
Erica Bäckström
AAAnna Abrahamsson
Anna Abrahamsson
BBBritta Bonn
Britta Bonn
KGKen Grime
Ken Grime
Significant pulmonary metabolism of inhaled drugs could have drug safety implications or influence pharmacological effectiveness. To study this in vitro, lung microsomes or S9 are often employed. Here, we have determined if rat and human lung microsomes are fit for purpose or whether it is better to use specific cells where drug-metabolizing enzymes are concentrated, such as alveolar type II (ATII) cells. Activities for major hepatic and pulmonary human drug-metabolizing enzymes are assessed and the data contextualized towards an in vivo setting using an ex vivo isolated perfused rat lung model. Very low rates of metabolism are observed in incubations with human ATII cells when compared to isolated hepatocytes and fewer of the substrates are found to be metabolized when compared to human lung microsomal incubations. Reactions selective for flavin-containing monooxygenases (FMOs), CYP1B1, CYP2C9, CYP2J2, and CYP3A4 all show significant rates in human lung microsomal incubations, but all activities are higher when rat lung microsomes are used. The work also demonstrates that a lung microsomal intrinsic clearance value towards the lower limit of detection for this parameter (3 µL/min/mg protein) results in a very low level of pulmonary metabolic clearance during the absorption period, for a drug dosed into the lung in vivo.

1 January 2018 in Drug Delivery
Verified
Journal Article
Open access
EBErica Bäckström
Erica Bäckström
GHGregory Hamm
Gregory Hamm
ANAnna Nilsson
Anna Nilsson
BFBritt-Marie Fihn
Britt-Marie Fihn
Nicole StrittmatterNicole Strittmatter
Nicole Strittmatter
MFMarkus Fridén
Markus Fridén
Treatment of respiratory disease with a drug delivered via inhalation is generally held as being beneficial as it provides direct access to the lung target site with a minimum systemic exposure. There is however only limited information of the regional localization of drug retention following inhalation. The aim of this study was to investigate the regional and histological localization of salmeterol retention in the lungs after inhalation and to compare it to systemic administration. Lung distribution of salmeterol delivered to rats via nebulization or intravenous (IV) injection was analyzed with high-resolution mass spectrometry imaging (MSI). Salmeterol was widely distributed in the entire section at 5 min after inhalation, by 15 min it was preferentially retained in bronchial tissue. Via a novel dual-isotope study, where salmeterol was delivered via inhalation and d3-salmeterol via IV to the same rat, could the effective gain in drug concentration associated with inhaled delivery relative to IV, expressed as a site-specific lung targeting factor, was 5-, 31-, and 45-fold for the alveolar region, bronchial sub-epithelium and epithelium, respectively. We anticipate that this MSI-based framework for quantifying regional and histological lung targeting by inhalation will accelerate discovery and development of local and more precise treatments of respiratory disease.

7 September 2020 in European Respiratory Journal
Verified
Conference Paper
Closed access
EBErica Bäckström
Erica Bäckström
BFBritt-Marie Fihn
Britt-Marie Fihn
TETeodor Erngren
Teodor Erngren
WLWalter Lindberg
Walter Lindberg
LOLina Odqvist
Lina Odqvist
KGKen Grime
Ken Grime
Broncho-alveolar lavage (BAL) is routinely used for collection of cells from the alveolar space and for sampling of epithelial lining fluid (ELF) in lungs in preclinical studies. Urea is present in all tissue at the same concentration and therefore is commonly used as a dilution marker of the BAL fluid to calculate back to compound concentration in ELF. The aim of the present study was to investigate the accuracy of ELF concentration determination and the possible extraction from surrounding tissue of compounds with diverse physicochemical properties, using different BAL volumes and repeated BAL procedure. Propranolol, diazepam, indomethacin, AZD4721, and anakinra were delivered as an intravenous (IV) bolus dose followed by an IV infusion for 4 h to reach steady state. BAL was performed with 1 mL, 4 mL, or repeatedly with 4 mL and samples from BAL, plasma and lung tissue were taken for bioanalysis. Repeated BAL procedure revealed significant extraction from tissue as the concentration in sequential BAL fluid samples decreased slowly: >60% of the concentration of propranolol in the first BAL fluid sample was still present in the fifth sample of BAL fluid. BAL procedure with 4 mL resulted in more extraction of urea as well as compounds from tissue and/or blood compared to BAL procedure with 1 mL. Small molecules (propranolol, diazepam, indomethacin, AZD4721) were extracted from tissue to a higher degree than the large protein drug anakinra. The present study clearly demonstrates that BAL procedure results in extraction of urea and compounds from surrounding tissue and the procedure is therefore not fit for the purpose of determination of compound concentrations in ELF.